Institutional members access full text with Ovid®

Share this article on:

Omalizumab in chronic urticaria

Metz, Martin; Maurer, Marcus

Current Opinion in Allergy & Clinical Immunology: August 2012 - Volume 12 - Issue 4 - p 406–411
doi: 10.1097/ACI.0b013e328355365a
PHARMACOTHERAPY AND EVIDENCE BASED MEDICINE: Edited by David A. Khan and Enrico Compalati

Purpose of review: The current EAACI/GA2LEN/EDF/WAO treatment guidelines for the management of urticaria recommend omalizumab as fourth-line therapy. Within the last year, many reports of omalizumab treatment in chronic urticaria have been published.

Recent findings: Two multicenter, randomized, placebo-controlled trials in chronic spontaneous urticaria have shown excellent efficacy of omalizumab. Furthermore, in various case series and case reports, omalizumab has been shown to be effective also in inducible urticarias; however, no randomized placebo-controlled trial has been performed yet to thoroughly investigate the efficacy of omalizumab in inducible urticarias.

Summary: In this review, all published information on the use of omalizumab in urticaria will be summarized and discussed with special emphasis on reports published within the last year. The available data indicate that omalizumab is an effective and well tolerated drug in antihistamine-resistant chronic urticaria.

Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Berlin, Germany

Correspondence to Professor Dr med. Marcus Maurer, MD, Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin, Germany. Tel: +49 30 450 518043; fax: +49 30 450 518972; e-mail: marcus.maurer@charite.de

Copyright © 2012 Wolters Kluwer Health, Inc. All rights reserved.